Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus pneumoniae type 23F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
This is a pneumococcal conjugate vaccine component consisting of the purified capsular polysaccharide from *Streptococcus pneumoniae* serotype 23F, chemically linked to the non-toxic diphtheria toxin variant CRM197 as a carrier protein. The conjugation enhances immunogenicity by inducing a T-cell dependent immune response, resulting in improved antibody production and immunological memory compared to unconjugated polysaccharide vaccines. It is used as an active immunization agent for the prevention of invasive pneumococcal diseases such as pneumonia and bacteremia caused by *S. pneumoniae* serotype 23F, particularly in infants and young children[1][3][5]. This antigen is included in multivalent pneumococcal vaccines like Prevnar/Prevenar.
- Brand names
- PrevnarPrevenarSynflorix
- Other names
- Streptococcus pneumoniae type 23F conjugate vaccinePneumococcal conjugate vaccine serotype 23F (CRM197)PNCRM7 (when part of heptavalent formulation)Streptococcus pneumoniae type 23f capsular polysaccharide diphtheria CRM197 protein conjugate antigen
02
Targets
Human B-cell receptor recognizing Streptococcus pneumoniae serotype 23F capsular polysaccharide epitopesTCR-CRM197 (CRM197-specific T-cell receptor)Streptococcus pneumoniae serotype 23F capsular polysaccharide
Beyond the preview
Go deeper on Streptococcus pneumoniae type 23F capsular polysaccharide diphtheria CRM197 protein conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Streptococcus pneumoniae type 23F capsular polysaccharide diphtheria CRM197 protein conjugate antigen.